Invention Grant
US09024024B2 Quinazoline based EGFR inhibitors containing a zinc binding moiety
有权
含有锌结合部分的基于喹唑啉的EGFR抑制剂
- Patent Title: Quinazoline based EGFR inhibitors containing a zinc binding moiety
- Patent Title (中): 含有锌结合部分的基于喹唑啉的EGFR抑制剂
-
Application No.: US14088804Application Date: 2013-11-25
-
Publication No.: US09024024B2Publication Date: 2015-05-05
- Inventor: Changgeng Qian , Xiong Cai , Stephen Gould , Haixiao Zhai
- Applicant: Curis, Inc.
- Applicant Address: US MA Lexington
- Assignee: Curis, Inc.
- Current Assignee: Curis, Inc.
- Current Assignee Address: US MA Lexington
- Agency: Elmore Patent Law Group, P.C.
- Agent Edgar W. Harlan; Carolyn S. Elmore, Esq.
- Main IPC: C07D239/94
- IPC: C07D239/94 ; C07D403/12 ; C07D405/04 ; C07D401/12 ; C07D405/12 ; C07D409/12
Abstract:
The present invention relates to quinazoline containing zinc-binding moiety based derivatives of Formula (IV) below. These compounds have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and are useful in the treatment of EGFR-TK related diseases and disorders such as cancer. These compounds may further act as HDAC inhibitors.
Public/Granted literature
- US20140221403A1 QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY Public/Granted day:2014-08-07
Information query
